{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T08:52:13.994005+00:00","company":{"ticker":"PYXS","cik":1782223,"company_name":"Pyxis Oncology, Inc."},"pagination":{"limit":100,"returned":8,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"executive_change","fact_key":"9ab73f3ab6","cik":1782223,"ticker":"PYXS","company_name":"Pyxis Oncology, Inc.","filed_at":"2026-04-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2026-04-29","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Lara Sullivan resigned as Director at Pyxis Oncology, Inc..","evidence_excerpt":"Also on the Effective Date, Dr. Sullivan resigned from the Board of Directors of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-193940","anchor_url":"https://secwatch.observer/filing/0001193125-26-193940#claim-9ab73f3ab6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526193940/0001193125-26-193940-index.htm"},{"fact_type":"executive_change","fact_key":"b4e5b0baaf","cik":1782223,"ticker":"PYXS","company_name":"Pyxis Oncology, Inc.","filed_at":"2026-04-30T23:59:59+00:00","payload":{"action":"separated","action_category":"departure","departure_tone":"routine","effective_date":"2026-04-29","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Lara Sullivan departed as Chief Executive Officer at Pyxis Oncology, Inc..","evidence_excerpt":"On April 29, 2026 (the “Effective Date”), the Separation Agreement between the Company and Dr. Sullivan became binding and effective, addressing Dr. Sullivan’s separation from the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-193940","anchor_url":"https://secwatch.observer/filing/0001193125-26-193940#claim-b4e5b0baaf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526193940/0001193125-26-193940-index.htm"},{"fact_type":"executive_change","fact_key":"58c091a31a","cik":1782223,"ticker":"PYXS","company_name":"Pyxis Oncology, Inc.","filed_at":"2025-03-18T23:59:59+00:00","payload":{"action":"assumed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-03-18","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Lara S. Sullivan changed role as Chief Medical Officer at Pyxis Oncology, Inc..","evidence_excerpt":"Lara S. Sullivan, M.D., President and Chief Executive Officer will assume the role of Chief Medical Officer along with her current role as President and Chief Executive Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-040767","anchor_url":"https://secwatch.observer/filing/0000950170-25-040767#claim-58c091a31a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025040767/0000950170-25-040767-index.htm"},{"fact_type":"executive_change","fact_key":"92fb570fc3","cik":1782223,"ticker":"PYXS","company_name":"Pyxis Oncology, Inc.","filed_at":"2025-03-18T23:59:59+00:00","payload":{"action":"stepping down","action_category":"departure","departure_tone":"routine","effective_date":"2025-03-18","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":"Lara S. Sullivan","successor_named":true},"claim":"Ken Kobayashi departed as Chief Medical Officer at Pyxis Oncology, Inc..","evidence_excerpt":"On March 18, 2025, the Company announced that Ken Kobayashi, M.D., F.A.C.P, is stepping down from his position as the Company's Chief Medical Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-040767","anchor_url":"https://secwatch.observer/filing/0000950170-25-040767#claim-92fb570fc3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025040767/0000950170-25-040767-index.htm"},{"fact_type":"executive_change","fact_key":"87f1e2adea","cik":1782223,"ticker":"PYXS","company_name":"Pyxis Oncology, Inc.","filed_at":"2024-06-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-10","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael A. Metzger was appointed as Director at Pyxis Oncology, Inc..","evidence_excerpt":"On June 10, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Michael A. Metzger, to its Board of Directors (the “Board”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-157911","anchor_url":"https://secwatch.observer/filing/0001193125-24-157911#claim-87f1e2adea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312524157911/0001193125-24-157911-index.htm"},{"fact_type":"earnings_release","fact_key":"ef5771414ffb271c10574f8326b768d7b0116911","cik":1782223,"ticker":"PYXS","company_name":"Pyxis Oncology, Inc.","filed_at":"2024-05-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":null},"claim":"Pyxis Oncology, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided a corporate update.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-059093","anchor_url":"https://secwatch.observer/filing/0000950170-24-059093#claim-ef5771414ffb271c10574f8326b768d7b0116911","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024059093/0000950170-24-059093-index.htm"},{"fact_type":"earnings_release","fact_key":"3d91a738a72172b7334ef54043510ce843365eac","cik":1782223,"ticker":"PYXS","company_name":"Pyxis Oncology, Inc.","filed_at":"2024-03-21T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$73.8 million, or ($1.85) per common share","period_text":"the full year ended December 31, 2023","report_date":"2024-03-21","result_type":"reported_results","revenue_text":null},"claim":"Pyxis Oncology, Inc. reported the full year ended December 31, 2023 results: net income $73.8 million, or ($1.85) per common share.","evidence_excerpt":"Net loss was $73.8 million, or ($1.85) per common share, for the year ended December 31, 2023, compared to $120.7 million, or ($3.65) per common share, for the year ended December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-034427","anchor_url":"https://secwatch.observer/filing/0000950170-24-034427#claim-3d91a738a72172b7334ef54043510ce843365eac","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024034427/0000950170-24-034427-index.htm"},{"fact_type":"executive_change","fact_key":"e5b5263b27","cik":1782223,"ticker":"PYXS","company_name":"Pyxis Oncology, Inc.","filed_at":"2024-03-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-12","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Santhosh Palani, Ph.D., CFA was appointed as Director at Pyxis Oncology, Inc..","evidence_excerpt":"On March 12, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Santhosh Palani, Ph.D., CFA ® , to its Board of Directors (the “Board”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-030817","anchor_url":"https://secwatch.observer/filing/0000950170-24-030817#claim-e5b5263b27","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024030817/0000950170-24-030817-index.htm"}]}